Astellas and Medivation have enrolled first patients in Treatment Registry for Outcomes in CRPC Patients (TRUMPET) study, which is designed to better understand the unique needs and treatment patterns for patients with castration-resistant prostate cancer (CRPC).
The prospective and observational patient registry will enrol and assess 2,000 patients diagnosed with CRPC from urology and oncology sites across the US.
Under the study, the firms will also collect data from the primary caregivers of patients, comprising spouses, family members and friends.
Astellas Pharma global development senior vice president Dr Jeffrey Bloss said: "While there have been many treatment advances in prostate cancer over the past few years, there is still a great deal for us to learn.
"The insights from TRUMPET can directly impact our research and increase our understanding of important treatment considerations."
The registry will follow patients with CRPC and participating caregivers for up to six years to collect information about the management of the disease, comprising patterns of care, treatment decisions and settings and physician referral patterns.
In addition, the study will track information about patient health-related quality of life outcomes, work productivity and treatment satisfaction and caregiver health-related quality of life outcomes associated with managing a patient with CRPC.
The study is expected to be completed in 2020.
Vanderbilt University Medical Centre urologic surgery department chair Dr David Penson said: "TRUMPET will expand our scientific understanding of CRPC to help healthcare professionals, patients and their loved ones make more informed decisions about their care."
Image: Micrograph of prostatic adenocarcinoma, conventional (acinar) type, the most common form of prostate cancer. Photo: courtesy of Nephron.